Home Healthcare Healthcare Services Neurology Clinical Trials Market

Neurology Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design (Interventional, Observational, Expanded Access), By Indication (Epilepsy, Parkinson's Disease (PD), Huntington's Disease, Stroke, Traumatic Brain Injury (TBI), Amyotrophic Lateral Sclerosis (ALS), Muscle regeneration, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: June 03, 2026 | Author: Jay Mehta | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Neurology Clinical Trials Market, By Phase 2022-2034 (USD MILLION/ Units)
    1. Phase I
    2. Phase II
    3. Phase III
    4. Phase IV
  2. Neurology Clinical Trials Market, By Study Design 2022-2034 (USD MILLION/ Units)
    1. Interventional
    2. Observational
    3. Expanded Access
  3. Neurology Clinical Trials Market, By Indication 2022-2034 (USD MILLION/ Units)
    1. Epilepsy
    2. Parkinson's Disease (PD)
    3. Huntington's Disease
    4. Stroke
    5. Traumatic Brain Injury (TBI)
    6. Amyotrophic Lateral Sclerosis (ALS)
    7. Muscle regeneration
    8. Others
  4. Regional Neurology Clinical Trials Market
    1. North America
      1. North America Neurology Clinical Trials Market By Phase 2022-2034 (USD MILLION/ Units)
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
      2. North America Neurology Clinical Trials Market By Study Design 2022-2034 (USD MILLION/ Units)
        1. Interventional
        2. Observational
        3. Expanded Access
      3. North America Neurology Clinical Trials Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Epilepsy
        2. Parkinson's Disease (PD)
        3. Huntington's Disease
        4. Stroke
        5. Traumatic Brain Injury (TBI)
        6. Amyotrophic Lateral Sclerosis (ALS)
        7. Muscle regeneration
        8. Others
      4. U.S.
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Interventional
        6. Observational
        7. Expanded Access
        8. Epilepsy
        9. Parkinson's Disease (PD)
        10. Huntington's Disease
        11. Stroke
        12. Traumatic Brain Injury (TBI)
        13. Amyotrophic Lateral Sclerosis (ALS)
        14. Muscle regeneration
        15. Others
      5. Canada
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Interventional
        6. Observational
        7. Expanded Access
        8. Epilepsy
        9. Parkinson's Disease (PD)
        10. Huntington's Disease
        11. Stroke
        12. Traumatic Brain Injury (TBI)
        13. Amyotrophic Lateral Sclerosis (ALS)
        14. Muscle regeneration
        15. Others
    2. Europe
      1. Europe Neurology Clinical Trials Market By Phase 2022-2034 (USD MILLION/ Units)
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
      2. Europe Neurology Clinical Trials Market By Study Design 2022-2034 (USD MILLION/ Units)
        1. Interventional
        2. Observational
        3. Expanded Access
      3. Europe Neurology Clinical Trials Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Epilepsy
        2. Parkinson's Disease (PD)
        3. Huntington's Disease
        4. Stroke
        5. Traumatic Brain Injury (TBI)
        6. Amyotrophic Lateral Sclerosis (ALS)
        7. Muscle regeneration
        8. Others
      4. U.K.
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Interventional
        6. Observational
        7. Expanded Access
        8. Epilepsy
        9. Parkinson's Disease (PD)
        10. Huntington's Disease
        11. Stroke
        12. Traumatic Brain Injury (TBI)
        13. Amyotrophic Lateral Sclerosis (ALS)
        14. Muscle regeneration
        15. Others
      5. Germany
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Interventional
        6. Observational
        7. Expanded Access
        8. Epilepsy
        9. Parkinson's Disease (PD)
        10. Huntington's Disease
        11. Stroke
        12. Traumatic Brain Injury (TBI)
        13. Amyotrophic Lateral Sclerosis (ALS)
        14. Muscle regeneration
        15. Others
      6. France
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Interventional
        6. Observational
        7. Expanded Access
        8. Epilepsy
        9. Parkinson's Disease (PD)
        10. Huntington's Disease
        11. Stroke
        12. Traumatic Brain Injury (TBI)
        13. Amyotrophic Lateral Sclerosis (ALS)
        14. Muscle regeneration
        15. Others
      7. Spain
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Interventional
        6. Observational
        7. Expanded Access
        8. Epilepsy
        9. Parkinson's Disease (PD)
        10. Huntington's Disease
        11. Stroke
        12. Traumatic Brain Injury (TBI)
        13. Amyotrophic Lateral Sclerosis (ALS)
        14. Muscle regeneration
        15. Others
      8. Italy
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Interventional
        6. Observational
        7. Expanded Access
        8. Epilepsy
        9. Parkinson's Disease (PD)
        10. Huntington's Disease
        11. Stroke
        12. Traumatic Brain Injury (TBI)
        13. Amyotrophic Lateral Sclerosis (ALS)
        14. Muscle regeneration
        15. Others
      9. Russia
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Interventional
        6. Observational
        7. Expanded Access
        8. Epilepsy
        9. Parkinson's Disease (PD)
        10. Huntington's Disease
        11. Stroke
        12. Traumatic Brain Injury (TBI)
        13. Amyotrophic Lateral Sclerosis (ALS)
        14. Muscle regeneration
        15. Others
      10. Nordic
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Interventional
        6. Observational
        7. Expanded Access
        8. Epilepsy
        9. Parkinson's Disease (PD)
        10. Huntington's Disease
        11. Stroke
        12. Traumatic Brain Injury (TBI)
        13. Amyotrophic Lateral Sclerosis (ALS)
        14. Muscle regeneration
        15. Others
      11. Benelux
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Interventional
        6. Observational
        7. Expanded Access
        8. Epilepsy
        9. Parkinson's Disease (PD)
        10. Huntington's Disease
        11. Stroke
        12. Traumatic Brain Injury (TBI)
        13. Amyotrophic Lateral Sclerosis (ALS)
        14. Muscle regeneration
        15. Others
      12. Rest of Europe
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Interventional
        6. Observational
        7. Expanded Access
        8. Epilepsy
        9. Parkinson's Disease (PD)
        10. Huntington's Disease
        11. Stroke
        12. Traumatic Brain Injury (TBI)
        13. Amyotrophic Lateral Sclerosis (ALS)
        14. Muscle regeneration
        15. Others
    3. APAC
      1. APAC Neurology Clinical Trials Market By Phase 2022-2034 (USD MILLION/ Units)
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
      2. APAC Neurology Clinical Trials Market By Study Design 2022-2034 (USD MILLION/ Units)
        1. Interventional
        2. Observational
        3. Expanded Access
      3. APAC Neurology Clinical Trials Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Epilepsy
        2. Parkinson's Disease (PD)
        3. Huntington's Disease
        4. Stroke
        5. Traumatic Brain Injury (TBI)
        6. Amyotrophic Lateral Sclerosis (ALS)
        7. Muscle regeneration
        8. Others
      4. China
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Interventional
        6. Observational
        7. Expanded Access
        8. Epilepsy
        9. Parkinson's Disease (PD)
        10. Huntington's Disease
        11. Stroke
        12. Traumatic Brain Injury (TBI)
        13. Amyotrophic Lateral Sclerosis (ALS)
        14. Muscle regeneration
        15. Others
      5. Korea
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Interventional
        6. Observational
        7. Expanded Access
        8. Epilepsy
        9. Parkinson's Disease (PD)
        10. Huntington's Disease
        11. Stroke
        12. Traumatic Brain Injury (TBI)
        13. Amyotrophic Lateral Sclerosis (ALS)
        14. Muscle regeneration
        15. Others
      6. Japan
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Interventional
        6. Observational
        7. Expanded Access
        8. Epilepsy
        9. Parkinson's Disease (PD)
        10. Huntington's Disease
        11. Stroke
        12. Traumatic Brain Injury (TBI)
        13. Amyotrophic Lateral Sclerosis (ALS)
        14. Muscle regeneration
        15. Others
      7. India
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Interventional
        6. Observational
        7. Expanded Access
        8. Epilepsy
        9. Parkinson's Disease (PD)
        10. Huntington's Disease
        11. Stroke
        12. Traumatic Brain Injury (TBI)
        13. Amyotrophic Lateral Sclerosis (ALS)
        14. Muscle regeneration
        15. Others
      8. Australia
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Interventional
        6. Observational
        7. Expanded Access
        8. Epilepsy
        9. Parkinson's Disease (PD)
        10. Huntington's Disease
        11. Stroke
        12. Traumatic Brain Injury (TBI)
        13. Amyotrophic Lateral Sclerosis (ALS)
        14. Muscle regeneration
        15. Others
      9. Taiwan
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Interventional
        6. Observational
        7. Expanded Access
        8. Epilepsy
        9. Parkinson's Disease (PD)
        10. Huntington's Disease
        11. Stroke
        12. Traumatic Brain Injury (TBI)
        13. Amyotrophic Lateral Sclerosis (ALS)
        14. Muscle regeneration
        15. Others
      10. South East Asia
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Interventional
        6. Observational
        7. Expanded Access
        8. Epilepsy
        9. Parkinson's Disease (PD)
        10. Huntington's Disease
        11. Stroke
        12. Traumatic Brain Injury (TBI)
        13. Amyotrophic Lateral Sclerosis (ALS)
        14. Muscle regeneration
        15. Others
      11. Rest of Asia-Pacific
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Interventional
        6. Observational
        7. Expanded Access
        8. Epilepsy
        9. Parkinson's Disease (PD)
        10. Huntington's Disease
        11. Stroke
        12. Traumatic Brain Injury (TBI)
        13. Amyotrophic Lateral Sclerosis (ALS)
        14. Muscle regeneration
        15. Others
    4. Middle East and Africa
      1. Middle East and Africa Neurology Clinical Trials Market By Phase 2022-2034 (USD MILLION/ Units)
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
      2. Middle East and Africa Neurology Clinical Trials Market By Study Design 2022-2034 (USD MILLION/ Units)
        1. Interventional
        2. Observational
        3. Expanded Access
      3. Middle East and Africa Neurology Clinical Trials Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Epilepsy
        2. Parkinson's Disease (PD)
        3. Huntington's Disease
        4. Stroke
        5. Traumatic Brain Injury (TBI)
        6. Amyotrophic Lateral Sclerosis (ALS)
        7. Muscle regeneration
        8. Others
      4. UAE
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Interventional
        6. Observational
        7. Expanded Access
        8. Epilepsy
        9. Parkinson's Disease (PD)
        10. Huntington's Disease
        11. Stroke
        12. Traumatic Brain Injury (TBI)
        13. Amyotrophic Lateral Sclerosis (ALS)
        14. Muscle regeneration
        15. Others
      5. Turkey
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Interventional
        6. Observational
        7. Expanded Access
        8. Epilepsy
        9. Parkinson's Disease (PD)
        10. Huntington's Disease
        11. Stroke
        12. Traumatic Brain Injury (TBI)
        13. Amyotrophic Lateral Sclerosis (ALS)
        14. Muscle regeneration
        15. Others
      6. Saudi Arabia
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Interventional
        6. Observational
        7. Expanded Access
        8. Epilepsy
        9. Parkinson's Disease (PD)
        10. Huntington's Disease
        11. Stroke
        12. Traumatic Brain Injury (TBI)
        13. Amyotrophic Lateral Sclerosis (ALS)
        14. Muscle regeneration
        15. Others
      7. South Africa
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Interventional
        6. Observational
        7. Expanded Access
        8. Epilepsy
        9. Parkinson's Disease (PD)
        10. Huntington's Disease
        11. Stroke
        12. Traumatic Brain Injury (TBI)
        13. Amyotrophic Lateral Sclerosis (ALS)
        14. Muscle regeneration
        15. Others
      8. Egypt
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Interventional
        6. Observational
        7. Expanded Access
        8. Epilepsy
        9. Parkinson's Disease (PD)
        10. Huntington's Disease
        11. Stroke
        12. Traumatic Brain Injury (TBI)
        13. Amyotrophic Lateral Sclerosis (ALS)
        14. Muscle regeneration
        15. Others
      9. Nigeria
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Interventional
        6. Observational
        7. Expanded Access
        8. Epilepsy
        9. Parkinson's Disease (PD)
        10. Huntington's Disease
        11. Stroke
        12. Traumatic Brain Injury (TBI)
        13. Amyotrophic Lateral Sclerosis (ALS)
        14. Muscle regeneration
        15. Others
      10. Rest of MEA
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Interventional
        6. Observational
        7. Expanded Access
        8. Epilepsy
        9. Parkinson's Disease (PD)
        10. Huntington's Disease
        11. Stroke
        12. Traumatic Brain Injury (TBI)
        13. Amyotrophic Lateral Sclerosis (ALS)
        14. Muscle regeneration
        15. Others
    5. LATAM
      1. LATAM Neurology Clinical Trials Market By Phase 2022-2034 (USD MILLION/ Units)
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
      2. LATAM Neurology Clinical Trials Market By Study Design 2022-2034 (USD MILLION/ Units)
        1. Interventional
        2. Observational
        3. Expanded Access
      3. LATAM Neurology Clinical Trials Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Epilepsy
        2. Parkinson's Disease (PD)
        3. Huntington's Disease
        4. Stroke
        5. Traumatic Brain Injury (TBI)
        6. Amyotrophic Lateral Sclerosis (ALS)
        7. Muscle regeneration
        8. Others
      4. Brazil
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Interventional
        6. Observational
        7. Expanded Access
        8. Epilepsy
        9. Parkinson's Disease (PD)
        10. Huntington's Disease
        11. Stroke
        12. Traumatic Brain Injury (TBI)
        13. Amyotrophic Lateral Sclerosis (ALS)
        14. Muscle regeneration
        15. Others
      5. Mexico
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Interventional
        6. Observational
        7. Expanded Access
        8. Epilepsy
        9. Parkinson's Disease (PD)
        10. Huntington's Disease
        11. Stroke
        12. Traumatic Brain Injury (TBI)
        13. Amyotrophic Lateral Sclerosis (ALS)
        14. Muscle regeneration
        15. Others
      6. Argentina
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Interventional
        6. Observational
        7. Expanded Access
        8. Epilepsy
        9. Parkinson's Disease (PD)
        10. Huntington's Disease
        11. Stroke
        12. Traumatic Brain Injury (TBI)
        13. Amyotrophic Lateral Sclerosis (ALS)
        14. Muscle regeneration
        15. Others
      7. Chile
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Interventional
        6. Observational
        7. Expanded Access
        8. Epilepsy
        9. Parkinson's Disease (PD)
        10. Huntington's Disease
        11. Stroke
        12. Traumatic Brain Injury (TBI)
        13. Amyotrophic Lateral Sclerosis (ALS)
        14. Muscle regeneration
        15. Others
      8. Colombia
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Interventional
        6. Observational
        7. Expanded Access
        8. Epilepsy
        9. Parkinson's Disease (PD)
        10. Huntington's Disease
        11. Stroke
        12. Traumatic Brain Injury (TBI)
        13. Amyotrophic Lateral Sclerosis (ALS)
        14. Muscle regeneration
        15. Others
      9. Rest of LATAM
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Interventional
        6. Observational
        7. Expanded Access
        8. Epilepsy
        9. Parkinson's Disease (PD)
        10. Huntington's Disease
        11. Stroke
        12. Traumatic Brain Injury (TBI)
        13. Amyotrophic Lateral Sclerosis (ALS)
        14. Muscle regeneration
        15. Others
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.